Secondary Issues

Orchid Pharma OFS fully subscribed

Business Line  

The offer-for-sale in Orchid Pharma by its promoter received strong response from both non-institutional (HNI) and retail investors. While the HNI portion was subscribed by 1.14 times, the retail portion got subscribed 3.45 times.

Want to receive such news items in your inbox? Click Here to sign up for a trial.

2021 © TSJ Media Pvt Ltd. All rights reserved.